Q3 EPS Forecast for Assembly Biosciences Raised by Analyst

Key Points

• HC Wainwright raised Assembly Biosciences’ Q3 2026 EPS forecast to a loss of $0.44 per share from $0.69 and now projects FY2026 earnings of $2.28 per share. The firm maintained its Buy rating and $50 price target.
• Assembly Biosciences recently reported a quarterly loss of $0.20 per share, beating the $0.72 consensus estimate, while revenue of $13.37 million exceeded expectations of $8.60 million.
• Analyst sentiment remains generally positive, with five Buy ratings and one Sell rating producing a “Moderate Buy” consensus and an average price target of $44.

Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) - Investment analysts at HC Wainwright boosted their Q3 2026 EPS estimates for shares of Assembly Biosciences in a research note issued on Tuesday, August 18th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will earn ($0.44) per share for the quarter, up from their previous forecast of ($0.69). HC Wainwright currently has a "Buy" rating and a $50.00 target price on the stock. The consensus estimate for Assembly Biosciences' current full-year earnings is $1.90 per share. HC Wainwright also issued estimates for Assembly Biosciences' Q4 2026 earnings at $3.19 EPS, FY2026 earnings at $2.28 EPS, Q1 2027 earnings at $0.02 EPS, Q2 2027 earnings at ($0.86) EPS, Q3 2027 earnings at ($0.87) EPS and FY2027 earnings at ($0.02) EPS.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.52. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%. The firm had revenue of $13.37 million for the quarter, compared to analyst estimates of $8.60 million.

A number of other equities research analysts also recently commented on the company. Wall Street Zen downgraded Assembly Biosciences from a "strong-buy" rating to a "hold" rating in a research report on Saturday, May 16th. Mizuho set a $45.00 price target on Assembly Biosciences and gave the stock an "outperform" rating in a report on Monday, June 15th. Guggenheim reissued a "buy" rating and set a $43.00 price objective on shares of Assembly Biosciences in a research report on Thursday, May 28th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Assembly Biosciences in a research report on Friday, July 17th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $44.00.

Assembly Biosciences Stock Performance

Shares of Assembly Biosciences stock opened at $33.84 on Thursday. The firm has a market capitalization of $688.98 million, a price-to-earnings ratio of 33.18 and a beta of 1.10. Assembly Biosciences has a fifty-two week low of $20.23 and a fifty-two week high of $39.71. The stock has a 50 day moving average of $26.66 and a 200 day moving average of $27.50.

Institutional Trading of Assembly Biosciences

Several institutional investors have recently added to or reduced their stakes in ASMB. Acadian Asset Management LLC raised its position in Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company's stock valued at $219,000 after purchasing an additional 6,823 shares during the period. Geode Capital Management LLC boosted its position in shares of Assembly Biosciences by 6.9% during the second quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company's stock worth $925,000 after buying an additional 3,312 shares during the period. Vanguard Group Inc. boosted its position in shares of Assembly Biosciences by 97.8% during the third quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company's stock worth $12,854,000 after buying an additional 248,287 shares during the period. ADAR1 Capital Management LLC acquired a new stake in shares of Assembly Biosciences in the third quarter valued at $485,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Assembly Biosciences in the third quarter valued at $3,120,000. Institutional investors and hedge funds own 19.92% of the company's stock.

Key Headlines Impacting Assembly Biosciences

Here are the key news stories impacting Assembly Biosciences this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to $2.28 from $1.90 and sharply improved its Q1 2027 forecast to a profit of $0.02 per share from a $0.16 loss. These revisions suggest stronger expected near-term earnings. HC Wainwright Reiterates Buy Rating for Assembly Biosciences
• Positive Sentiment: The firm also narrowed its projected losses for Q3 2026 to $0.44 per share from $0.69, Q2 2027 to $0.86 from $1.18, and Q3 2027 to $0.87 from $1.18. Its FY2027 loss estimate improved significantly to $0.02 per share from $0.77, indicating expectations for Assembly Biosciences to approach breakeven.
• Positive Sentiment: Analysts maintained the $50 price objective and Buy rating, while a separate report said Assembly Biosciences carries a Moderate Buy consensus rating. The positive ratings and higher earnings forecasts are likely the main reasons investor sentiment has improved. Assembly Biosciences Receives Consensus Rating of Moderate Buy
• Neutral Sentiment: Not all revisions were positive: HC Wainwright reduced its Q4 2026 EPS forecast to $3.19 from $3.69 and trimmed its Q4 2027 estimate to $1.63 from $1.66. However, the firm still expects FY2026 profitability and retained its Buy recommendation.

About Assembly Biosciences

Assembly Biosciences, Inc NASDAQ: ASMB is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company's core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly's research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company's lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source